APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Relapsed Acute Myeloid Leukemia Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Relapsed Acute Myeloid Leukemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025195 pages

Choose your research edition.

Industry ResearchRelapsed Acute Myeloid Leukemia Drug Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Relapsed Acute Myeloid Leukemia Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Relapsed Acute Myeloid Leukemia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Relapsed Acute Myeloid Leukemia Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Relapsed Acute Myeloid Leukemia Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Relapsed Acute Myeloid Leukemia Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Relapsed Acute Myeloid Leukemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Relapsed Acute Myeloid Leukemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Relapsed Acute Myeloid Leukemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Relapsed Acute Myeloid Leukemia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Relapsed Acute Myeloid Leukemia Drug include 4SC AG, Amgen Inc., AbbVie Inc., AstraZeneca Plc, CTI BioPharma Corp., Cornerstone Pharmaceuticals, Inc., Celgene Corporation, Calithera Biosciences, Inc. and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Relapsed Acute Myeloid Leukemia Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Relapsed Acute Myeloid Leukemia Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Relapsed Acute Myeloid Leukemia Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Relapsed Acute Myeloid Leukemia Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Relapsed Acute Myeloid Leukemia Drug Segment by Company

4SC AG

Amgen Inc.

AbbVie Inc.

AstraZeneca Plc

CTI BioPharma Corp.

Cornerstone Pharmaceuticals, Inc.

Celgene Corporation

Calithera Biosciences, Inc.

Bristol-Myers Squibb Company

Boston Biomedical, Inc.

Boehringer Ingelheim GmbH

BioLineRx, Ltd.

AVEO Pharmaceuticals, Inc.

Astex Pharmaceuticals, Inc.

Astellas Pharma Inc.

Array BioPharma Inc.

Arog Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

Relapsed Acute Myeloid Leukemia Drug Segment by Type

aNK Program

AT-9283

BI-836858

BL-8040

Binimetinib

Others

Relapsed Acute Myeloid Leukemia Drug Segment by Application

Clinic

Hospital

Others

Relapsed Acute Myeloid Leukemia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Relapsed Acute Myeloid Leukemia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Relapsed Acute Myeloid Leukemia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Relapsed Acute Myeloid Leukemia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Relapsed Acute Myeloid Leukemia Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Relapsed Acute Myeloid Leukemia Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Relapsed Acute Myeloid Leukemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Relapsed Acute Myeloid Leukemia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Relapsed Acute Myeloid Leukemia Drug Industry Trends Table 2. Relapsed Acute Myeloid Leukemia Drug Industry Drivers Table 3. Relapsed Acute Myeloid Leukemia Drug Industry Opportunities and Challenges Table 4. Relapsed Acute Myeloid Leukemia Drug Industry Restraints Table 5. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Manufacturers Table 9. Global Relapsed Acute Myeloid Leukemia Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Relapsed Acute Myeloid Leukemia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Relapsed Acute Myeloid Leukemia Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Relapsed Acute Myeloid Leukemia Drug Manufacturers, Product Type & Application Table 13. Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Relapsed Acute Myeloid Leukemia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of aNK Program Table 17. Major Manufacturers of AT-9283 Table 18. Major Manufacturers of BI-836858 Table 19. Major Manufacturers of BL-8040 Table 20. Major Manufacturers of Binimetinib Table 21. Major Manufacturers of Others Table 22. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2026) & (K Units) Table 24. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2027-2032) & (K Units) Table 25. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2021-2026) Table 26. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2027-2032) Table 27. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2026) & (K Units) Table 29. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2027-2032) & (K Units) Table 30. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2021-2026) Table 31. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Hospital Table 34. Major Manufacturers of Others Table 35. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2026) & (K Units) Table 37. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2027-2032) & (K Units) Table 38. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2021-2026) Table 39. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2027-2032) Table 40. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2026) & (K Units) Table 42. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2027-2032) & (K Units) Table 43. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2021-2026) Table 44. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2027-2032) Table 45. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2021-2026) Table 48. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Relapsed Acute Myeloid Leukemia Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 52. North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 53. Europe Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 55. Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Relapsed Acute Myeloid Leukemia Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2021-2026) Table 66. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2027-2032) Table 67. 4SC AG Company Information Table 68. 4SC AG Business Overview Table 69. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 71. 4SC AG Recent Development Table 72. Amgen Inc. Company Information Table 73. Amgen Inc. Business Overview Table 74. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 76. Amgen Inc. Recent Development Table 77. AbbVie Inc. Company Information Table 78. AbbVie Inc. Business Overview Table 79. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 81. AbbVie Inc. Recent Development Table 82. AstraZeneca Plc Company Information Table 83. AstraZeneca Plc Business Overview Table 84. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 86. AstraZeneca Plc Recent Development Table 87. CTI BioPharma Corp. Company Information Table 88. CTI BioPharma Corp. Business Overview Table 89. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 91. CTI BioPharma Corp. Recent Development Table 92. Cornerstone Pharmaceuticals, Inc. Company Information Table 93. Cornerstone Pharmaceuticals, Inc. Business Overview Table 94. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 96. Cornerstone Pharmaceuticals, Inc. Recent Development Table 97. Celgene Corporation Company Information Table 98. Celgene Corporation Business Overview Table 99. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 101. Celgene Corporation Recent Development Table 102. Calithera Biosciences, Inc. Company Information Table 103. Calithera Biosciences, Inc. Business Overview Table 104. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 106. Calithera Biosciences, Inc. Recent Development Table 107. Bristol-Myers Squibb Company Company Information Table 108. Bristol-Myers Squibb Company Business Overview Table 109. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 111. Bristol-Myers Squibb Company Recent Development Table 112. Boston Biomedical, Inc. Company Information Table 113. Boston Biomedical, Inc. Business Overview Table 114. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 116. Boston Biomedical, Inc. Recent Development Table 117. Boehringer Ingelheim GmbH Company Information Table 118. Boehringer Ingelheim GmbH Business Overview Table 119. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 121. Boehringer Ingelheim GmbH Recent Development Table 122. BioLineRx, Ltd. Company Information Table 123. BioLineRx, Ltd. Business Overview Table 124. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 126. BioLineRx, Ltd. Recent Development Table 127. AVEO Pharmaceuticals, Inc. Company Information Table 128. AVEO Pharmaceuticals, Inc. Business Overview Table 129. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 131. AVEO Pharmaceuticals, Inc. Recent Development Table 132. Astex Pharmaceuticals, Inc. Company Information Table 133. Astex Pharmaceuticals, Inc. Business Overview Table 134. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 136. Astex Pharmaceuticals, Inc. Recent Development Table 137. Astellas Pharma Inc. Company Information Table 138. Astellas Pharma Inc. Business Overview Table 139. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 141. Astellas Pharma Inc. Recent Development Table 142. Array BioPharma Inc. Company Information Table 143. Array BioPharma Inc. Business Overview Table 144. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 146. Array BioPharma Inc. Recent Development Table 147. Arog Pharmaceuticals, Inc. Company Information Table 148. Arog Pharmaceuticals, Inc. Business Overview Table 149. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 151. Arog Pharmaceuticals, Inc. Recent Development Table 152. Agios Pharmaceuticals, Inc. Company Information Table 153. Agios Pharmaceuticals, Inc. Business Overview Table 154. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 156. Agios Pharmaceuticals, Inc. Recent Development Table 157. Actinium Pharmaceuticals, Inc. Company Information Table 158. Actinium Pharmaceuticals, Inc. Business Overview Table 159. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 160. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio Table 161. Actinium Pharmaceuticals, Inc. Recent Development Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Relapsed Acute Myeloid Leukemia Drug Distributors List Table 165. Relapsed Acute Myeloid Leukemia Drug Customers List Table 166. Research Programs/Design for This Report Table 167. Authors List of This Report Table 168. Secondary Sources Table 169. Primary Sources List of Figures Figure 1. Relapsed Acute Myeloid Leukemia Drug Product Image Figure 2. Global Relapsed Acute Myeloid Leukemia Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Relapsed Acute Myeloid Leukemia Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Relapsed Acute Myeloid Leukemia Drug Sales (2021-2032) & (K Units) Figure 5. Global Relapsed Acute Myeloid Leukemia Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Relapsed Acute Myeloid Leukemia Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. aNK Program Image Figure 9. AT-9283 Image Figure 10. BI-836858 Image Figure 11. BL-8040 Image Figure 12. Binimetinib Image Figure 13. Others Image Figure 14. Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2021-2032) Figure 17. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2021-2032) Figure 20. Clinic Image Figure 21. Hospital Image Figure 22. Others Image Figure 23. Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2021-2032) Figure 26. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2032) Figure 43. China Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Relapsed Acute Myeloid Leukemia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Relapsed Acute Myeloid Leukemia Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Relapsed Acute Myeloid Leukemia Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Relapsed Acute Myeloid Leukemia Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • aNK Program
  • AT-9283
  • BI-836858
  • BL-8040
  • Binimetinib
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • 4SC AG
  • Amgen Inc.
  • AbbVie Inc.
  • AstraZeneca Plc
  • CTI BioPharma Corp.
  • Cornerstone Pharmaceuticals, Inc.
  • Celgene Corporation
  • Calithera Biosciences, Inc.
  • Bristol-Myers Squibb Company
  • Boston Biomedical, Inc.
  • Boehringer Ingelheim GmbH
  • BioLineRx, Ltd.
  • AVEO Pharmaceuticals, Inc.
  • Astex Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • Array BioPharma Inc.
  • Arog Pharmaceuticals, Inc.
  • Agios Pharmaceuticals, Inc.
  • Actinium Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Relapsed Acute Myeloid Leukemia Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Relapsed Acute Myeloid Leukemia Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Relapsed Acute Myeloid Leukemia Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Relapsed Acute Myeloid Leukemia Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Relapsed Acute Myeloid Leukemia Drug Market Dynamics
  1. 2.1 Relapsed Acute Myeloid Leukemia Drug Industry Trends
  2. 2.2 Relapsed Acute Myeloid Leukemia Drug Industry Drivers
  3. 2.3 Relapsed Acute Myeloid Leukemia Drug Industry Opportunities and Challenges
  4. 2.4 Relapsed Acute Myeloid Leukemia Drug Industry Restraints
3 Relapsed Acute Myeloid Leukemia Drug Market by Manufacturers
  1. 3.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Relapsed Acute Myeloid Leukemia Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Relapsed Acute Myeloid Leukemia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Relapsed Acute Myeloid Leukemia Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Relapsed Acute Myeloid Leukemia Drug Manufacturers, Product Type & Application
  7. 3.7 Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Relapsed Acute Myeloid Leukemia Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Relapsed Acute Myeloid Leukemia Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Relapsed Acute Myeloid Leukemia Drug Tier 1, Tier 2, and Tier 3
4 Relapsed Acute Myeloid Leukemia Drug Market by Type
  1. 4.1 Relapsed Acute Myeloid Leukemia Drug Type Introduction
  2. 4.1.1 aNK Program
  3. 4.1.2 AT-9283
  4. 4.1.3 BI-836858
  5. 4.1.4 BL-8040
  6. 4.1.5 Binimetinib
  7. 4.1.6 Others
  8. 4.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type
  9. 4.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type
  13. 4.3.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2021-2032)
5 Relapsed Acute Myeloid Leukemia Drug Market by Application
  1. 5.1 Relapsed Acute Myeloid Leukemia Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application
  6. 5.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application
  10. 5.3.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2021-2032)
6 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region
  1. 6.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region
  1. 7.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region
  2. 7.1.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032)
  8. 7.2.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032)
  11. 7.3.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 4SC AG
  2. 8.1.1 4SC AG Company Information
  3. 8.1.2 4SC AG Business Overview
  4. 8.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  6. 8.1.5 4SC AG Recent Developments
  7. 8.2 Amgen Inc.
  8. 8.2.1 Amgen Inc. Company Information
  9. 8.2.2 Amgen Inc. Business Overview
  10. 8.2.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  12. 8.2.5 Amgen Inc. Recent Developments
  13. 8.3 AbbVie Inc.
  14. 8.3.1 AbbVie Inc. Company Information
  15. 8.3.2 AbbVie Inc. Business Overview
  16. 8.3.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  18. 8.3.5 AbbVie Inc. Recent Developments
  19. 8.4 AstraZeneca Plc
  20. 8.4.1 AstraZeneca Plc Company Information
  21. 8.4.2 AstraZeneca Plc Business Overview
  22. 8.4.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  24. 8.4.5 AstraZeneca Plc Recent Developments
  25. 8.5 CTI BioPharma Corp.
  26. 8.5.1 CTI BioPharma Corp. Company Information
  27. 8.5.2 CTI BioPharma Corp. Business Overview
  28. 8.5.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  30. 8.5.5 CTI BioPharma Corp. Recent Developments
  31. 8.6 Cornerstone Pharmaceuticals, Inc.
  32. 8.6.1 Cornerstone Pharmaceuticals, Inc. Company Information
  33. 8.6.2 Cornerstone Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  36. 8.6.5 Cornerstone Pharmaceuticals, Inc. Recent Developments
  37. 8.7 Celgene Corporation
  38. 8.7.1 Celgene Corporation Company Information
  39. 8.7.2 Celgene Corporation Business Overview
  40. 8.7.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  42. 8.7.5 Celgene Corporation Recent Developments
  43. 8.8 Calithera Biosciences, Inc.
  44. 8.8.1 Calithera Biosciences, Inc. Company Information
  45. 8.8.2 Calithera Biosciences, Inc. Business Overview
  46. 8.8.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  48. 8.8.5 Calithera Biosciences, Inc. Recent Developments
  49. 8.9 Bristol-Myers Squibb Company
  50. 8.9.1 Bristol-Myers Squibb Company Company Information
  51. 8.9.2 Bristol-Myers Squibb Company Business Overview
  52. 8.9.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  54. 8.9.5 Bristol-Myers Squibb Company Recent Developments
  55. 8.10 Boston Biomedical, Inc.
  56. 8.10.1 Boston Biomedical, Inc. Company Information
  57. 8.10.2 Boston Biomedical, Inc. Business Overview
  58. 8.10.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  60. 8.10.5 Boston Biomedical, Inc. Recent Developments
  61. 8.11 Boehringer Ingelheim GmbH
  62. 8.11.1 Boehringer Ingelheim GmbH Company Information
  63. 8.11.2 Boehringer Ingelheim GmbH Business Overview
  64. 8.11.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  66. 8.11.5 Boehringer Ingelheim GmbH Recent Developments
  67. 8.12 BioLineRx, Ltd.
  68. 8.12.1 BioLineRx, Ltd. Company Information
  69. 8.12.2 BioLineRx, Ltd. Business Overview
  70. 8.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  72. 8.12.5 BioLineRx, Ltd. Recent Developments
  73. 8.13 AVEO Pharmaceuticals, Inc.
  74. 8.13.1 AVEO Pharmaceuticals, Inc. Company Information
  75. 8.13.2 AVEO Pharmaceuticals, Inc. Business Overview
  76. 8.13.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  78. 8.13.5 AVEO Pharmaceuticals, Inc. Recent Developments
  79. 8.14 Astex Pharmaceuticals, Inc.
  80. 8.14.1 Astex Pharmaceuticals, Inc. Company Information
  81. 8.14.2 Astex Pharmaceuticals, Inc. Business Overview
  82. 8.14.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  84. 8.14.5 Astex Pharmaceuticals, Inc. Recent Developments
  85. 8.15 Astellas Pharma Inc.
  86. 8.15.1 Astellas Pharma Inc. Company Information
  87. 8.15.2 Astellas Pharma Inc. Business Overview
  88. 8.15.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  90. 8.15.5 Astellas Pharma Inc. Recent Developments
  91. 8.16 Array BioPharma Inc.
  92. 8.16.1 Array BioPharma Inc. Company Information
  93. 8.16.2 Array BioPharma Inc. Business Overview
  94. 8.16.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  96. 8.16.5 Array BioPharma Inc. Recent Developments
  97. 8.17 Arog Pharmaceuticals, Inc.
  98. 8.17.1 Arog Pharmaceuticals, Inc. Company Information
  99. 8.17.2 Arog Pharmaceuticals, Inc. Business Overview
  100. 8.17.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  102. 8.17.5 Arog Pharmaceuticals, Inc. Recent Developments
  103. 8.18 Agios Pharmaceuticals, Inc.
  104. 8.18.1 Agios Pharmaceuticals, Inc. Company Information
  105. 8.18.2 Agios Pharmaceuticals, Inc. Business Overview
  106. 8.18.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  108. 8.18.5 Agios Pharmaceuticals, Inc. Recent Developments
  109. 8.19 Actinium Pharmaceuticals, Inc.
  110. 8.19.1 Actinium Pharmaceuticals, Inc. Company Information
  111. 8.19.2 Actinium Pharmaceuticals, Inc. Business Overview
  112. 8.19.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product Portfolio
  114. 8.19.5 Actinium Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Relapsed Acute Myeloid Leukemia Drug Value Chain Analysis
  2. 9.1.1 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Relapsed Acute Myeloid Leukemia Drug Production Mode & Process
  6. 9.2 Relapsed Acute Myeloid Leukemia Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Relapsed Acute Myeloid Leukemia Drug Distributors
  9. 9.2.3 Relapsed Acute Myeloid Leukemia Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst